Cav3.2-expressing low-threshold C fibres in human hairy skin contribute to cold allodynia--a non-TRPV1- and non-TRPM8-dependent phenomenon.
It is generally agreed that cold allodynia is a consequence of impaired (Aδ-fibre-mediated) central inhibition of C-nociceptive inputs. However, it is also known that C polymodal nociceptors are not activated at innocuous low temperatures. Recently, we demonstrated the contribution of C-tactile fibres to tactile allodynia. In this study, we investigated whether this, or a related, C-fibre class contributes to cold allodynia. In 30 healthy and 3 chronic pain subjects, a series of normally innocuous localised thermal stimuli were applied to the skin overlying a painful tibialis anterior muscle (induced by infusion of hypertonic saline). The effects of thermal stimulation on muscle pain were observed before and after compression blockade of myelinated fibres. Furthermore, intradermal capsaicin, menthol and TTA-A2 were used for desensitisation of TRPV1, TRPM8, and T-type calcium (Cav3.2) channels, respectively. Before muscle pain, all thermal stimuli were reported as nonpainful regardless of whether myelinated fibres were conducting or not. During muscle pain, dynamic skin cooling (32°C → 20°C) evoked significant and reproducible increases in the overall pain intensity (allodynia). This increase was short lived and locked to the dynamic phase of cooling with pain levels returning to baseline during sustained cooling. Dynamic warming (32°C → 39°C) had no effect on pain levels. Cold allodynia persisted after nerve compression and TRPV1 and TRPM8 desensitisation but was abolished by localised Cav3.2 blockade. In clinical subjects, C-fibre-mediated allodynia was observed without the need for experimental pain-producing manipulations. In conclusion, cold allodynia represents a non-TRPV1- and non-TRPM8-dependent phenomenon, which is mediated by low-threshold Cav3.2-expressing C fibres.
Department of Integrative Physiology, School of Medicine, University of Western Sydney, Penrith, Australia.
Mohamad S
MS
Samour
Saad S
SS
Nagi
David A
DA
Mahns
D000328:Adult; D044482:Benzeneacetamides / Q000008:administration & dosage; D002211:Capsaicin / Q000008:administration & dosage; D003080:Cold Temperature / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008610:Menthol / Q000008:administration & dosage; D063806:Myalgia / Q000503:physiopathology*; D036421:Nerve Fibers, Unmyelinated / Q000187:drug effects / Q000502:physiology*; D010147:Pain Measurement / Q000379:methods; D058748:Pain Perception / Q000187:drug effects / Q000502:physiology*; D010812:Physical Stimulation / Q000379:methods; D011725:Pyridines / Q000008:administration & dosage; D012684:Sensory Thresholds / Q000502:physiology*; D012867:Skin / Q000187:drug effects / Q000294:innervation*; D050053:TRPM Cation Channels / Q000378:metabolism; D050916:TRPV Cation Channels / Q000378:metabolism; D013697:Thermosensing / Q000187:drug effects / Q000502:physiology; D055815:Young Adult
C553486:2-(4-cyclopropylphenyl)-N-(1-(5-((2,2,2-trifluoroethyl)oxo)pyridin-2-yl)ethyl)acetamide; D044482:Benzeneacetamides; D011725:Pyridines; D050053:TRPM Cation Channels; C425966:TRPM8 protein, human; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human; D008610:Menthol; D002211:Capsaicin